262425-92-3

Usage

Structure

Consists of a benzene ring with a hydroxyl group and a pyrrolidinyl group attached via an ether linkage
Commonly used as a reagent in organic synthesis and medicinal chemistry
Potential applications in pharmacology for the development of new drugs
May have uses in the synthesis of novel materials and in the study of biological processes

Specific content

Benzene ring with a hydroxyl group and a pyrrolidinyl group attached via an ether linkage
Reagent in organic synthesis and medicinal chemistry
Potential applications in pharmacology for the development of new drugs
Possible uses in the synthesis of novel materials and in the study of biological processes

Upstream product

• 26116-47-2 4-(2-tetrahydro-1H-1-pyrrolylethoxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 63675-89-8 methyl 4-<2-(1-pyrrolidinyl)ethoxy>benzoate 
• 623-05-2 (4-hydroxyphenyl)methanol 

Downstream Products

• 1335047-82-9 1-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]naphthalen-2-ol 
• 1323402-44-3 3-(1-oxo-4-(4-(2-(pyrrolidin-1-yl)ethoxy)benzyloxy)isoindolin-2-yl)piperidine-2,6-dione 
• 1323407-27-7 methyl 5-amino-5-oxo-4-(1-oxo-4-(4-(2-pyrrolidin-1-ylethoxy)benzyloxy)isoindolin-2-yl)pentanoate 
• 859392-91-9 3,7-dimethoxy-10-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 859392-89-5 7-methoxy-10-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 752968-15-3 1-[2-(4-chloromethyl-phenoxy)-ethyl]-pyrrolidine 

Relevant academic research and scientific papers

Compound and preparation method and application thereof

The invention relates to the field of medicinal chemistry and pharmacotherapeutics, in particular to a bazedoxifene analog compound and a preparation method thereof, application of the bazedoxifene analog compound in a GP130 small molecule inhibitor and t

OXABOROLE ESTERS AND USES THEREOF

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER

Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The invention provides compounds of Formula (I) : wherein R1 is hydrogen, OH, halo, -CN, -NO2, -N=0, -NHOQ2, -OQ2, -SOQ2, -SO2Q2, -SON(Q2)2, - SO2N(Q2)2, -N(Q2)2, -C(O)OQ2, -C(O)Q2, -C(O)N(Q2)2, -C(=NQ2)NQ2, -NQ2C(=NQ2)NQ2, - C(O)N(Q2)(OQ2), -N(Q2)C(O)-Q2, -N(Q2)C(O)N(Q2)2, -N(Q2)C(O)O-Q2, -N(Q2)SO2Q2, -N(Q2)SOQ2, aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, and heteroaryl ring optionally including 1-3 substituents independently selected Q3; R2 and R3 are each independently hydrogen, OH, oxo, aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, optionally substituted with 1-3 of Q1 or Q2; X is a branched or straight C1-12 aliphatic chain wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, -CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, - O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, -SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-; G and G1 are each independently a branched or straight C1-2 aliphatic chain, or heterocycloalkyl, wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, - CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, -O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, - SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-, and pharmaceutically acceptable salts, solvates or prodaigs thereof, as well as methods of treating estrogen receptor mediated diseases and disorders using the compounds of Formula (I).

Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators

In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2- hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen- 1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl) piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist.

Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators

A series of estrogen receptor ligands based on benzothieno[3,2-b]indole were synthesized and their binding affinity for estrogen receptor subtypes (ERα and ERβ) and effects on mouse uterus and bone were evaluated. Some of these compounds showed strong bin

Structure-activity relationship studies on 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase

Leukotriene B4 (LTB4) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA4 hydrolase is the rate-limiting step for LTB4 production, this enzyme represents an attractive pharmacological target for the suppression of LTB4 production. From an in- house screening program, SC-22716 (1, 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA4 hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA4 hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.